BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 34591424)

  • 1. Evaluation of serum levels of selected cytokine receptors in adult B-cell precursor acute lymphoblastic leukemia and their association with prognostic factors and survival.
    Horacek JM; Kupsa T; Vanek J; Jakl M; Stajer M; Jebavy L; Zak P
    Exp Oncol; 2021 Sep; 43(3):234-236. PubMed ID: 34591424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.
    Zugmaier G; Gökbuget N; Klinger M; Viardot A; Stelljes M; Neumann S; Horst HA; Marks R; Faul C; Diedrich H; Reichle A; Brüggemann M; Holland C; Schmidt M; Einsele H; Bargou RC; Topp MS
    Blood; 2015 Dec; 126(24):2578-84. PubMed ID: 26480933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.
    Lepretre S; Touzart A; Vermeulin T; Picquenot JM; Tanguy-Schmidt A; Salles G; Lamy T; Béné MC; Raffoux E; Huguet F; Chevallier P; Bologna S; Bouabdallah R; Benichou J; Brière J; Moreau A; Tallon-Simon V; Seris S; Graux C; Asnafi V; Ifrah N; Macintyre E; Dombret H
    J Clin Oncol; 2016 Feb; 34(6):572-80. PubMed ID: 26644537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
    Cario G; Rhein P; Mitlöhner R; Zimmermann M; Bandapalli OR; Romey R; Moericke A; Ludwig WD; Ratei R; Muckenthaler MU; Kulozik AE; Schrappe M; Stanulla M; Karawajew L
    Haematologica; 2014 Jan; 99(1):103-10. PubMed ID: 23911702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
    Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
    Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma.
    Gupta M; Stenson M; O'Byrne M; Maurer MJ; Habermann T; Cerhan JR; Weiner GW; Witzig TE
    Ann Oncol; 2016 Jan; 27(1):165-72. PubMed ID: 26487586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic significance of Wilms' tumor gene 1 (WT1) expression at diagnosis in adults with Ph-negative B cell precursor acute lymphoblastic leukemia.
    Qin YZ; Jiang Q; Xu LP; Jiang H; Wang Y; Zhao XS; Li ZR; Lai YY; Liu YR; Zhang XH; Liu KY; Huang XJ
    Ann Hematol; 2019 Nov; 98(11):2551-2559. PubMed ID: 31493003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy].
    Wang J; Huang X; Jiang B; Qin Y; Bao L; Jiang H; Chen H; Jia J; Yang S; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):120-5. PubMed ID: 24606652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High RASD1 transcript levels at diagnosis predicted poor survival in adult B-cell acute lymphoblastic leukemia patients.
    Wang S; Wang C; Wang W; Hao Q; Liu Y
    Leuk Res; 2019 May; 80():26-32. PubMed ID: 30925311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
    Kantarjian HM; DeAngelo DJ; Stelljes M; Liedtke M; Stock W; Gökbuget N; O'Brien SM; Jabbour E; Wang T; Liang White J; Sleight B; Vandendries E; Advani AS
    Cancer; 2019 Jul; 125(14):2474-2487. PubMed ID: 30920645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of minimal residual disease in young adults with standard-risk/Ph-negative precursor B-acute lymphoblastic leukemia: results of prospective study.
    Salah-Eldin M; Abousamra NK; Azzam H
    Med Oncol; 2014 May; 31(5):938. PubMed ID: 24692146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
    Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
    J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Gökbuget N; Kantarjian HM; Brüggemann M; Stein AS; Bargou RC; Dombret H; Fielding AK; Heffner L; Rigal-Huguet F; Litzow M; O'Brien S; Zugmaier G; Gao S; Nagorsen D; Forman SJ; Topp MS
    Blood Adv; 2019 Oct; 3(20):3033-3037. PubMed ID: 31648325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic importance of the soluble form of IL-2 receptorα (sIL-2Rα) and its relationship with surface expression of IL-2Rα (CD25) of lymphoma cells in diffuse large B-cell lymphoma treated with CHOP-like regimen with or without rituximab: a retrospective analysis of 338 cases.
    Hashimoto Y; Yokohama A; Saitoh A; Nakahashi H; Toyama K; Mitsui T; Koiso H; Saitoh T; Handa H; Uchiumi H; Jinbo T; Murayama K; Matsumoto M; Sawamura M; Karasawa M; Murakami H; Hirato J; Nojima Y; Kojima M; Tsukamoto N
    J Clin Exp Hematop; 2013; 53(3):197-205. PubMed ID: 24369221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Application of imatinib in BCR- ABL positive acute lymphoblastic leukemia treatment in the real world].
    Wan YL; Wang Y; Liu BC; Liu X; Gong XY; Zhao XL; Wang TY; Jiang EL; Feng SZ; Han MZ; Qiu LG; Mi YC; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2016 Oct; 37(10):886-891. PubMed ID: 27801322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia.
    Bassan R; Rohatiner AZ; Lerede T; Di Bona E; Rambaldi A; Pogliani E; Rossi G; Fabris P; Morandi S; Casula P; Carter M; Lambertenghi-Deliliers G; Lister TA; Barbui T
    Hematol J; 2000; 1(4):226-34. PubMed ID: 11920195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
    Gökbuget N; Dombret H; Bonifacio M; Reichle A; Graux C; Faul C; Diedrich H; Topp MS; Brüggemann M; Horst HA; Havelange V; Stieglmaier J; Wessels H; Haddad V; Benjamin JE; Zugmaier G; Nagorsen D; Bargou RC
    Blood; 2018 Apr; 131(14):1522-1531. PubMed ID: 29358182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular diagnosis and clinical relevance of t(9;22), t(4;11) and t(1 ;19) chromosome abnormalities in a consecutive group of 141 adult patients with acute lymphoblastic leukemia.
    Rambaldi A; Attuati V; Bassan R; Neonato MG; Viero P; Battista R; Di Bona E; Rossi G; Pogliani E; Ruggeri M; Amaru R; Rivolta A; Giudici G; Biondi A; Barbui T
    Leuk Lymphoma; 1996 May; 21(5-6):457-66. PubMed ID: 9172811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG.
    Burke MJ; Salzer WL; Devidas M; Dai Y; Gore L; Hilden JM; Larsen E; Rabin KR; Zweidler-McKay PA; Borowitz MJ; Wood B; Heerema NA; Carroll AJ; Winick N; Carroll WL; Raetz EA; Loh ML; Hunger SP
    Haematologica; 2019 May; 104(5):986-992. PubMed ID: 30545921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of serum soluble interleukin-2 receptor-α in extranodal natural killer/T-cell lymphoma (ENKTL): a predictive biomarker for treatment efficacy and valuable prognostic factor.
    Wang L; Liao DZ; Zhang J; Xia ZJ; Peng XW; Lu Y
    Med Oncol; 2013 Dec; 30(4):723. PubMed ID: 24037346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.